Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.70 |
| ▸ | ITGAV | P06756 | 13/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.70 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983029 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| SCHEMBL7980899 | 0.86 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| SCHEMBL7445928 | 0.86 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| SCHEMBL7983202 | 0.81 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL8492415 | 0.81 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| SCHEMBL7445939 | 0.80 | ITGB3 (0.45) | ITGB3ITGAVITGA2B | |
| SCHEMBL7217668 | 0.78 | ITGB3 (0.74) | ITGB3ITGAVITGA2B | |
| SCHEMBL7983025 | 0.78 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| SCHEMBL7421593 | 0.76 | ITGB3 (0.49) | ITGB3ITGAVITGA2B | |
| SCHEMBL8853817 | 0.76 | MDM2 (0.42) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6191282-B1 | DERIVATIVES OF 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING IS USED AS ANTICARCINOGENIC AGENT AND ANTICOAGULANT | HOECHST MARION ROUSSEL (DE) | 2001-02-20 | — | — | US | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |